Drug Trial Radar · NCT06961344
An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM)
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
37
Actual
Start
Aug 18, 2025
Primary completion
Oct 29, 2026
Study completion Oct 29, 2026
Sponsor
- Lead sponsor
- Tisento TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- May 7, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the long-term safety and tolerability of zagociguat in patients with MELAS who completed study medication treatment in the lead-in study TIS6463-203. TIS6463-204 is evaluating zagociguat in an open-label extension study at the daily dose of 15mg. The study medication is a once daily oral table and will be provided at the clinic and/or shipped to the participant's home. Study assessments will be conducted during clinic visits which will occur at three months and then at six months. Thereafter, clinic visits will occur every six months.
Conditions
- Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)
Interventions
zagociguat 15mgDrug
once daily oral tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-emergent Adverse Events (TEAEs)Time frame: Day 1 through the Follow-up for treatment period 4 weeks after last dose of study medication.
Locations
16 sites in 5 countries. Site status is shown where the registry gives one.
UC San Diego - Altman Clinical and Translational Research Institute
La Jolla, California
Children's Hospital of Colorado
Aurora, Colorado
Rare Disease Research
Atlanta, Georgia
Massachusetts General Hospital
Boston, Massachusetts
Mount Sinai - Ichan School of Medicine
New York, New York
Akron Children's Hospital
Akron, Ohio
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Baylor College of Medicine
Houston, Texas
UT Health Houston
Houston, Texas
Neuroscience Research Australia
Sydney, New South Wales, Australia
Royal Melbourne Hospital
Melbourne, Victoria, Australia
LMU Klinikum, Friedrich-Baur-Institute, Department of Neurology
Munich, Germany
Neurologic Institute Carlo Besta of Milan
Milan, Italy
Fondazione Policlinico Universitario Agostino Gemelli
Rome, Italy
University College London Hospital. The National Hospital for Neurology and Neurosurgery, Centre for Neuromuscular Diseases
London, United Kingdom
The Newcastle upon Tyne NHS Foundation Trust
Newcastle upon Tyne, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.